Allarity Therapeutics (NASDAQ:ALLR) Trading Up 1.6% – Should You Buy?

Allarity Therapeutics, Inc. (NASDAQ:ALLR)’s share price shot up 1.6% during mid-day trading on Monday . The stock traded as high as $0.8630 and last traded at $0.8440. 100,250 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 174,101 shares. The stock had previously closed at $0.8307.

Analysts Set New Price Targets

ALLR has been the topic of several research analyst reports. Ascendiant Capital Markets lifted their price target on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Trading Up 1.6%

The stock has a market cap of $13.57 million, a PE ratio of -1.43 and a beta of 0.23. The business has a 50 day moving average of $1.09 and a 200-day moving average of $1.26.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, equities research analysts anticipate that Allarity Therapeutics, Inc. will post -78.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Allarity Therapeutics during the 2nd quarter valued at $27,000. Geode Capital Management LLC increased its holdings in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares during the period. XTX Topco Ltd acquired a new position in shares of Allarity Therapeutics during the second quarter valued at approximately $51,000. Citadel Advisors LLC bought a new stake in Allarity Therapeutics in the third quarter worth about $149,000. Finally, Capital Advisors Inc. OK bought a new position in shares of Allarity Therapeutics in the fourth quarter valued at $108,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.